PPTA Twitter

PlasmaProteins “Today, patients are living longer, more fruitful lives. I want tomorrow to be even brighter for patients, & I am committed to PPTA’s steadfast pledge to this goal.” #PlasmaProteins President & CEO @Efantis shares her excitement about her new role: bit.ly/2PX1A5r pic.twitter.com/goWVeZupoj
About 4 hours ago.
PlasmaProteins It’s important for policymakers to understand the impact of #plasmaprotein therapies. “These are not therapies that provide a small measure of comfort or a little bit of increased ability. These are life-saving and life-changing.” Read John’s story: bit.ly/2KLwONK pic.twitter.com/OYcw1jUyON
2 days ago.

IQPP Standards Public Review Period Now Open!

The following draft has been issued for public review:

In accordance with the procedures for developing PPTA Voluntary Standards, this document is hereby issued for public review, from April 18, 2019 until June 16, 2019. This is a proposed revision to Version 4.0.

All comments must be sent to Sonia Balboni at sbalboni@pptaglobal.org by June 16, 2019.

After the close of the comment period, all comments received in relation to the draft will be considered. If resolution to the comments results in substantive changes to the draft, another comment period may be initiated. If resolution to the comments results in no or minor changes, the draft will be implemented as part of the IQPP Voluntary Standards Program. Adequate notice will be provided prior to the implementation period of any PPTA standard.

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100